Pretreatment ctDNA findings in a cohort of 44 patients indicated that gene amplifications, particularly in FGFR1 (encoding fibroblast growth factor receptor 1) and CCNE1 (encoding cyclin E1) may serve as biomarkers for resistance to PSMA RPT (3), although these amplifications are not typically observed in tumor tissue of patients with mCRPC. This evidence concerns the gene FOLH1 and neoplasm.